ETF Building Blocks Channel Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Channel Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
ETF Prime ETF Prime: Tom Lydon Talks Pros & Cons of Market Cap Weighting By Aaron NeuwirthSeptember 1, 2021
Innovative ETFs Channel Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021
ETF Building Blocks Channel Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
ETF Building Blocks Channel Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
ETF Building Blocks Channel As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Innovative ETFs Channel Greater Regulatory Scrutiny Could Weigh on Biotech ETFs By Max ChenMarch 24, 2021
Innovative ETFs Channel Illumina Earnings, Forward Guidance Strengthen Biotech ETFs By Max ChenFebruary 12, 2021
Innovative ETFs Channel Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug By Max ChenJanuary 29, 2021
